TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 11/25/2025 at 19:15, 9 days 11 hours ago

Transgene launches a fundraising campaign for approximately 105 million euros
Transgene launches a fundraising of approximately 105 million euros through new share issuance to investors. Funding to advance myvac program for personalized cancer vaccines and ensure financial stability until early 2028

Fundraising Financial Stability Cancer Vaccines Transgene Myvac Program
BRIEF

published on 11/06/2025 at 08:35, 28 days 21 hours ago

Transgene to Present VacDesignR® Tool at ESMO AI 2025

Transgene VacDesignR® INTV ESMO AI 2025 HPV-negative Cancer
PRESS RELEASE

published on 11/06/2025 at 08:30, 28 days 21 hours ago

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Transgene to present VacDesignR® tool at ESMO-AI 2025 for optimized cancer vaccine design. Tool enhances virus efficiency and yield for individualized therapies

Cancer Vaccines Computational Tool Transgene VacDesignR ESMO-AI 2025
BRIEF

published on 11/04/2025 at 17:55, 1 month ago

Transgene presents its progress and financial situation as of Q3 2025

Funding Immunotherapy Transgene TG4050 SITC 2025
PRESS RELEASE

published on 11/04/2025 at 17:50, 1 month ago

Transgene Provides Business and Financial Update for Q3 2025
Transgene provides business and financial update for Q3 2025, including immunogenicity data of INTV TG4050 in Phase I study on HNSCC. Company focuses on cancer immunotherapies

Financial Update Transgene INTV TG4050 Cancer Immunotherapies HNSCC
BRIEF

published on 10/20/2025 at 08:35, 1 month 15 days ago

Transgene and BioInvent's BT-001 Shows Promising Antitumor Activity

Cancer Immunotherapy Transgene Oncolytic Virus BT-001 Antitumoral Activity
PRESS RELEASE

published on 10/20/2025 at 08:30, 1 month 15 days ago

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025

Transgene Oncolytic Virus BioInvent BT-001 Pembrolizumab
BRIEF

published on 06/13/2025 at 08:35, 5 months 21 days ago

Transgene Engages with Key Biotech Industry Platforms

Cancer Treatment Clinical Data Immunotherapy Transgene Biotech Meetings
PRESS RELEASE

published on 06/13/2025 at 08:30, 5 months 21 days ago

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com

Biotech Industry Clinical Data Transgene Immunothérapies Neoantigen Cancer Vaccine
BRIEF

published on 06/01/2025 at 19:20, 6 months 3 days ago

Transgene and NEC: Promising progress with the TG4050 vaccine

Immunotherapy Transgene Therapeutic Vaccine Clinical Phase Neoantigens

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE